H
Hiroshi Takayanagi
Researcher at University of Tokyo
Publications - 220
Citations - 30513
Hiroshi Takayanagi is an academic researcher from University of Tokyo. The author has contributed to research in topics: Osteoclast & RANKL. The author has an hindex of 74, co-authored 204 publications receiving 26654 citations. Previous affiliations of Hiroshi Takayanagi include University of Western Australia & National Presto Industries.
Papers
More filters
Journal ArticleDOI
Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts.
Hiroshi Takayanagi,Sunhwa Kim,Takako Koga,Takako Koga,Hiroshi Nishina,Masashi Isshiki,Hiroki Yoshida,Hiroki Yoshida,Akio Saiura,Miho Isobe,Miho Isobe,Taeko Yokochi,Jun-ichiro Inoue,Erwin F. Wagner,Tak W. Mak,Tatsuhiko Kodama,Tadatsugu Taniguchi +16 more
TL;DR: RANKL selectively induces NFATc1 expression via TRAF6 and c-Fos signaling pathways, and may represent a master switch for regulating terminal differentiation of osteoclasts, functioning downstream of RANKL.
Journal ArticleDOI
Osteoimmunology: shared mechanisms and crosstalk between the immune and bone systems
TL;DR: The two systems should be understood to be integrated and operating in the context of the 'osteoimmune' system, a heuristic concept that provides not only a framework for obtaining new insights by basic research, but also a scientific basis for the discovery of novel treatments for diseases related to both systems.
Journal ArticleDOI
Evidence for osteocyte regulation of bone homeostasis through RANKL expression
Tomoki Nakashima,Mikihito Hayashi,Takanobu Fukunaga,Kosaku Kurata,Masatsugu Oh-hora,Jian Q. Feng,Lynda F. Bonewald,Tatsuhiko Kodama,Anton Wutz,Erwin F. Wagner,Josef M. Penninger,Hiroshi Takayanagi,Hiroshi Takayanagi +12 more
TL;DR: It is found that purified osteocytes express a much higher amount of receptor activator of nuclear factor-κB ligand (RANKL) and have a greater capacity to support osteoclastogenesis in vitro than osteoblasts and bone marrow stromal cells.
Journal ArticleDOI
Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction
Kojiro Sato,Ayako Suematsu,Kazuo Okamoto,Akira Yamaguchi,Yasuyuki Morishita,Yuho Kadono,Sakae Tanaka,Tatsuhiko Kodama,Shizuo Akira,Yoichiro Iwakura,Daniel J. Cua,Hiroshi Takayanagi +11 more
TL;DR: Th17 is a powerful therapeutic target for the bone destruction associated with T cell activation and the interleukin (IL)-23–IL-17 axis, rather than the IL-12–IFN-γ axis, is critical for the onset phase of autoimmune arthritis.
Journal ArticleDOI
T-cell-mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-gamma.
Hiroshi Takayanagi,Kouetsu Ogasawara,Shigeaki Hida,Tomoki Chiba,Shigeo Murata,Kojiro Sato,Akinori Takaoka,Taeko Yokochi,Hiromi Oda,Keiji Tanaka,Kozo Nakamura,Tadatsugu Taniguchi +11 more
TL;DR: This study shows that there is cross-talk between the tumour necrosis factor and IFN families of cytokines, through which IFN-γ provides a negative link between T-cell activation and bone resorption and may offer a therapeutic approach to treat the inflammation-induced tissue breakdown.